Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Authors not listed
Affiliated Hospital to Academy of Military Medical Sciences · 2021
Abstract
The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Anonymous. (2021). A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome. <em>Affiliated Hospital to Academy of Military Medical Sciences</em>. https://clinicaltrials.gov/study/NCT04999943
Vancouver
Anonymous. A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome. Affiliated Hospital to Academy of Military Medical Sciences. 2021.
BibTeX
@misc{anon2021ARando,
title = {A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome},
author = {Anonymous},
journal = {Affiliated Hospital to Academy of Military Medical Sciences},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Tianjin Medical University Cancer Institute and Hospital 2023
Open access · US-GOV
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
Asfendiyarov Kazakh National Medical University 2024
Open access · US-GOV
Comparative Analysis of Risk Factors and Prediction of Frailty Syndrome
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2026
Open access · US-GOV
A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy
The University of Hong Kong 2022
Open access · US-GOV
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study
Optimal Acuity Corporation 2021
Open access · US-GOV
Observational Study of Vision Improvement in Patients With Retinal Disorders
Medivation, Inc. 2008
Open access · US-GOV